Paper Details

  1. Home
  2. Paper Details

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!

Author: SinghAwadhesh Kumar, SinghRitu

EditorialAn article in which the editor or publisher expresses their opinion or perspective on a particular topic or issue. Its purpose is to convey a specific message or idea to the reader.

Overview

This review discusses recent findings suggesting that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and the novel non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone may be effective in preventing the progression of diabetic kidney disease (DKD).
Paper Details　
Original Abstract of the Article :
Several pharmacological agents to prevent the progression of diabetic kidney disease (DKD) have been tested in patients with type 2 diabetes mellitus (T2DM) in the past two decades. With the exception of renin-angiotensin system blockers that have shown a significant reduction in the progression of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329844/

データ提供：米国国立医学図書館（NLM）

A Journey Through Two Decades of Diabetic Kidney Disease Treatments

Diabetic kidney disease (DKD) is a serious complication of diabetes that can lead to kidney failure. This study takes a comprehensive look at the evolution of DKD treatments over the past two decades. The researchers review the effectiveness of various pharmacological agents, including renin-angiotensin system blockers (RAS blockers), sodium-glucose cotransporter-2 inhibitors (SGLT-2i), and mineralocorticoid receptor antagonists (MRAs), in preventing the progression of DKD. The findings highlight the significant advances made in DKD treatment and the emerging role of SGLT-2i and MRAs in managing this challenging condition.

New Medications Offer Hope for Preventing DKD Progression

The study underscores the significant progress made in DKD treatment, with RAS blockers, SGLT-2i, and MRAs emerging as effective agents in slowing the progression of the disease. This finding offers hope for individuals with diabetes who are at risk of developing DKD.

Managing DKD: A Collaborative Approach is Essential

This research emphasizes the importance of a collaborative approach to managing DKD. It's essential to consult with a healthcare professional to discuss the most appropriate treatment plan based on your individual needs and medical history. It's also important to adhere to lifestyle recommendations, such as maintaining a healthy diet, exercising regularly, and managing blood sugar levels.

Dr.Camel's Conclusion

This study offers a comprehensive overview of the evolving landscape of DKD treatment. It highlights the crucial role of pharmacological interventions and underscores the importance of individualized care and lifestyle modifications in managing this challenging condition. It's like traversing a vast desert of medical knowledge, where research and clinical practice are constantly evolving to offer new paths for preventing and managing DKD.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-09-07
Further Info :

Pubmed ID

36051422

DOI: Digital Object Identifier

PMC9329844

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.